Scalp-cooling by DIGNICAP system for the prevention of chemotherapy-induced hair loss in breast cancer patients.

Breast Cancer - Local-Regional and Adjuvant Therapy
Session Type and Session Title: 
This abstract will not be presented at the 2010 ASCO Annual Meeting but has been published in conjunction with the meeting.
Abstract Number: 


J Clin Oncol 28, 2010 (suppl; abstr e11034)
M. Kato; Kato Breast Surgery Clinic, Kusatsu, Japan

Abstract Disclosures


Background: The DigniCap system (Dignitana AB, Sweden) is an established, highly effective and safe device to prevent hair loss by cooling the scalp. This study evaluates the DigniCap system and presents the results of scalp hypothermia on breast cancer patients undergoing chemotherapy. Methods: DigniCap is using a digitized system for controlled scalp-cooling with a refrigerator integrated into a control unit with the soft and tight-fitting silicon cap. Scalp temperature was maintained at +5 centigrades throughout drug administration and for at least 30 min after discontinuing the infusion. Photographs of each patient´s scalp were taken before starting chemotherapy. The evaluation was made using a visual analogue scale. All patients answered a questionnaire with 15 questions regarding physical and psychological issues. Results: From August 2007 to October 2009, 255 patients, aged 25-77 yrs (mean 47.4), with breast cancer were examined completely. The patients were treated with either paclitaxel (60 mg/m2 weekly) plus cyclophosphamide (500 mg/m2) (176 patients) or paclitaxel plus Herceptin combination (29 patients) or epirubicine (40 mg/m2 biweekly) plus cyclophosphamide (28 patients). Remaining 22 patients were treated either combination by 5FU, CPT-11, vinorelbine or CBDCA. The results were as follows: 141 patients (55.3%) were classed as grade 0, 68 patients (26.7%) as grade 1, 40 patients (15.7%) as grade 2 and 6 patients (2.4%) as grade 3. Conclusions: DigniCap system using scalp-cooling is effective method to prevent chemotherapy-induced hair loss in patients with cancer of the breast.